Baldwin Brothers Inc. MA Has $15.27 Million Holdings in Merck & Co., Inc. (MRK)
Baldwin Brothers Inc. MA reduced its holdings in Merck & Co., Inc. (NYSE:MRK) by 0.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 199,871 shares of the company’s stock after selling 1,381 shares during the period. Merck & Co., Inc. accounts for approximately 2.6% of Baldwin Brothers Inc. MA’s portfolio, making the stock its 7th largest position. Baldwin Brothers Inc. MA’s holdings in Merck & Co., Inc. were worth $15,272,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Third Point LLC bought a new position in Merck & Co., Inc. in the 3rd quarter worth approximately $319,230,000. PointState Capital LP bought a new stake in shares of Merck & Co., Inc. during the third quarter valued at approximately $8,513,000. Port Capital LLC bought a new stake in shares of Merck & Co., Inc. during the third quarter valued at approximately $1,028,000. Green Valley Investors LLC bought a new stake in shares of Merck & Co., Inc. during the third quarter valued at approximately $31,418,000. Finally, Carnegie Capital Asset Management LLC increased its position in shares of Merck & Co., Inc. by 24.2% during the third quarter. Carnegie Capital Asset Management LLC now owns 36,248 shares of the company’s stock valued at $2,756,000 after purchasing an additional 7,068 shares during the period. 73.36% of the stock is currently owned by institutional investors.
In other Merck & Co., Inc. news, Chairman Kenneth C. Frazier sold 231,566 shares of the company’s stock in a transaction on Tuesday, February 5th. The stock was sold at an average price of $78.08, for a total value of $18,080,673.28. Following the sale, the chairman now directly owns 923,516 shares in the company, valued at $72,108,129.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Rita A. Karachun sold 64,662 shares of the company’s stock in a transaction on Thursday, February 14th. The shares were sold at an average price of $78.96, for a total value of $5,105,711.52. Following the completion of the sale, the vice president now owns 53,327 shares in the company, valued at $4,210,699.92. The disclosure for this sale can be found here. Insiders sold 1,094,632 shares of company stock worth $87,840,652 over the last quarter. Company insiders own 0.32% of the company’s stock.
Shares of NYSE:MRK opened at $82.29 on Thursday. Merck & Co., Inc. has a fifty-two week low of $52.83 and a fifty-two week high of $83.47. The firm has a market capitalization of $223.57 billion, a price-to-earnings ratio of 18.96, a P/E/G ratio of 2.01 and a beta of 0.62. The company has a current ratio of 1.17, a quick ratio of 0.92 and a debt-to-equity ratio of 0.74.
Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Friday, February 1st. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.01. Merck & Co., Inc. had a return on equity of 36.83% and a net margin of 14.71%. The firm had revenue of $11 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same period in the prior year, the business posted $0.98 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year. As a group, research analysts predict that Merck & Co., Inc. will post 4.65 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 2.67%. The ex-dividend date is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 50.69%.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Recommended Story: Bond
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.